Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $10.6000 (-0.61%) ($10.6000 - $10.7650) on Fri. Nov. 24, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.37% (three month average) | RSI | 40 | Latest Price | $10.6000(-0.61%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.1% a day on average for past five trading days. | Weekly Trend | FOLD declines -1.7% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IVW(75%) IBB(70%) XBI(70%) QQQ(66%) SPY(66%) | Factors Impacting FOLD price | FOLD will decline at least -1.685% in a week (0% probabilities). UUP(-14%) TBT(-11%) VIXM(-8%) BNDX(-1%) URA(-0%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.685% (StdDev 3.37%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
Resistance Level | $10.85 | 5 Day Moving Average | $10.76(-1.49%) | 10 Day Moving Average | $10.66(-0.56%) | 20 Day Moving Average | $10.85(-2.3%) | To recent high | -20.6% | To recent low | 6.4% | Market Cap | $2.737b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |